## Jorge Sierra

## List of Publications by Year in descending order

Source: https:/|exaly.com/author-pdf/1219171/publications.pdf
Version: 2024-02-01

1
2

Prognostic impact of $\langle\mathrm{i}\rangle \mathrm{DNMT3A}\langle/ \mathrm{i}\rangle$ mutation in acute myeloid leukemia with mutated $\langle\mathrm{i}\rangle \mathrm{NPM} 1</ \mathrm{i}\rangle$.
Blood Advances, 2022, 6, 882-890.

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances, 2022, 6, 1193-1206.
2.5

26

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous
3 system involvement: aÂcase report and review of the literature. Journal of Medical Case Reports, 2021,
$0.4 \quad 8$ 15, 326.

Acute myeloid leukemia with <i>NPM1</i> mutation and favorable European LeukemiaNet category:
4 outcome after preemptive intervention based on measurable residual disease. British Journal of
1.2 Haematology, 2020, 191, 52-61.

5 UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia, 2020, 34, 2925-2933.

Allogeneic stem cell transplantation in AML with $t(6 ; 9)(p 23 ; q 34) ;<i>D E K a ̂ \in N U P 214</ i>$ shows a favourable
6 outcome when performed in first complete remission. British Journal of Haematology, 2020, 189,
1.2 920-925.
$7 \quad \begin{aligned} & \text { Validation of the European Leukemianet } 2017 \text { Prognostic Classification for Patients with De Novo } \\ & \text { Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). Blood, 2020, 136, 31-32. }\end{aligned}$
$8 \quad \begin{aligned} & \text { Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5ấezacytidine: Identification } \\ & \text { of responding patients. European Journal of Haematology, 2019, 103, 208-214. }\end{aligned}$
Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia
(AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease. Blood, 2019, 134, 289-289.

10 A 4-gene expression prognostic signature might guide post-remission therapy in patients with
intermediate-risk cytogenetic acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2394-2404.
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute
11 Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold
2.0

Value. Biology of Blood and Marrow Transplantation, 2018, 24, 55-63.
Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated
12 with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 \& 2012. Blood, 2015, 126, 2511-2511.

| 13 | Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 \& 2012. Blood, 2015, 126, 2514-2514. | 0.6 | 0 |
| :---: | :---: | :---: | :---: |
| 14 | Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 2013, 121, 2734-2738. | 0.6 | 246 |
| 15 | BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577. | 0.6 | 0 |
| 16 | Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. Journal of Clinical Oncology, 2012, 30, 735-741. | 0.8 | 251 |
| 17 | The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews Clinical Oncology, 2012, 9, 579-590. | 12.5 | 352 |

